DBV Technologies | Balance Sheet

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
39,402.80
114,583.10
323,381.00
256,473.00
137,880.00
122,770
Total Accounts Receivable
4,090.10
5,920.80
9,662.00
12,979.00
16,931.00
16,867
Inventories
6.60
124.10
-
-
-
1,566
Other Current Assets
315.60
937.90
1,850.00
2,725.00
2,054.00
4,265
Total Current Assets
43,815.00
121,565.90
334,893.00
272,177.00
156,865.00
145,468
Net Property, Plant & Equipment
1,734.10
2,224.90
5,581.00
12,482.00
17,808.00
20,219
Total Investments and Advances
278.10
484.60
1,328.00
1,435.00
1,678.00
5,601
Intangible Assets
63.00
28.80
94.00
96.00
123.00
29
Other Assets
82.30
-
-
-
-
-
Total Assets
45,972.60
124,304.30
341,896.00
286,190.00
176,474.00
171,317
ST Debt & Current Portion LT Debt
126.30
240.60
149.00
591.00
2,325.00
Accounts Payable
1,497.30
1,874.60
10,034.00
13,720.00
-
Income Tax Payable
56.10
114.30
388.00
504.00
428.00
Other Current Liabilities
2,554.50
3,322.10
5,450.00
14,187.00
33,177.00
Total Current Liabilities
4,234.10
5,551.70
16,021.00
29,002.00
35,930.00
Long-Term Debt
1,316.50
3,888.20
4,693.00
4,049.00
1,825.00
Provision for Risks & Charges
290.70
530.70
490.00
854.00
1,260.00
Other Liabilities
-
-
-
10,746.00
8,869.00
Total Liabilities
5,841.30
9,970.60
21,204.00
44,651.00
47,884.00
Common Equity (Total)
40,131.30
114,333.70
320,692.00
241,539.00
128,590.00
Total Shareholders' Equity
40,131.30
114,333.70
320,692.00
241,539.00
128,590.00
Total Equity
40,131.30
114,333.70
320,692.00
241,539.00
128,590.00
Liabilities & Shareholders' Equity
45,972.60
124,304.30
341,896.00
286,190.00
176,474.00

About DBV Technologies

View Profile
Address
177-181, avenue Pierre Brossolette
Montrouge Ile-de-France 92120
France
Employees -
Website http://www.dbv-technologies.com
Updated 07/08/2019
DBV Technologies SA is a clinical-stage biopharmaceutical company, which deals with conducting of research and development of epicutaneous immunotherapy products. It focuses on developing a novel technology platform called Viaskin, which is an electrostatic patch that offers a convenient, self-administered, non-invasive immunotherapy to patients. The company has designed two products candidates: Viaskin Peanut and Viaskin Milk.